AtriCure (NASDAQ:ATRC) Updates FY 2026 Earnings Guidance

AtriCure (NASDAQ:ATRC) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.090-0.150 for the period, compared to the consensus EPS estimate of -0.030. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $604.3 million.

AtriCure Trading Up 1.7%

ATRC stock opened at $31.46 on Wednesday. The business has a fifty day moving average price of $36.88 and a 200 day moving average price of $36.49. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.96 and a quick ratio of 2.99. AtriCure has a fifty-two week low of $28.29 and a fifty-two week high of $43.18. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -131.08 and a beta of 1.42.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Tuesday, February 17th. The medical device company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.10. AtriCure had a negative return on equity of 1.15% and a negative net margin of 2.14%.The company had revenue of $140.50 million for the quarter, compared to analysts’ expectations of $140.50 million. During the same quarter in the prior year, the business earned ($0.33) earnings per share. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. Analysts expect that AtriCure will post -0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ATRC. BTIG Research reissued a “buy” rating and set a $54.00 price objective on shares of AtriCure in a report on Wednesday, February 18th. JPMorgan Chase & Co. downgraded shares of AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 target price for the company. in a research note on Wednesday, February 11th. Canaccord Genuity Group decreased their price target on shares of AtriCure from $64.00 to $53.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Citizens Jmp lowered their price target on shares of AtriCure from $60.00 to $52.00 and set a “market outperform” rating for the company in a report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AtriCure in a report on Wednesday, January 21st. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, AtriCure currently has a consensus rating of “Moderate Buy” and an average price target of $48.43.

Institutional Investors Weigh In On AtriCure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATRC. AQR Capital Management LLC boosted its holdings in AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after buying an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of AtriCure by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after acquiring an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock valued at $27,830,000 after acquiring an additional 8,956 shares during the period. Jane Street Group LLC boosted its stake in AtriCure by 658.3% during the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after acquiring an additional 87,553 shares during the last quarter. Finally, Strs Ohio bought a new position in AtriCure during the 1st quarter worth approximately $158,000. Institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.